Actively Recruiting

Phase 1
Age: 17Years +
All Genders
NCT06287528

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-10

18

Participants Needed

7

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.

CONDITIONS

Official Title

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Who Can Participate

Age: 17Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must have relapsed or refractory acute lymphoblastic leukemia (ALL) meeting specified criteria for Philadelphia chromosome positive or negative disease
  • Signed informed consent form before any study procedures
  • Age 17 years or older for the first 3 patients, then age 12 years or older for additional patients
  • Documentation of CD19 positivity on leukemia cells if prior anti-CD19 treatment
  • History of prior allogeneic stem cell transplant allowed if at least 3 months prior and no recent graft versus host disease
  • Donor lymphocyte infusions allowed if at least 4 weeks before leukapheresis
  • History of secondary CNS or meningeal involvement allowed if not the only site of disease and no neurological symptoms
  • Adequate organ function including liver enzymes, bilirubin, kidney function, oxygen saturation, and heart function
  • ECOG performance status 0-1 or Lansky score 60 or higher for patients under 16 years
  • Prior CD19-targeted therapies allowed if CD19 positivity confirmed
Not Eligible

You will not qualify if you...

  • Active malignancy other than nonmelanoma skin cancer or low-risk localized solid tumors
  • Burkitt's leukemia, lymphoma, or CML in lymphoid blast crisis
  • Active or symptomatic CNS disease with high white blood cell count in cerebrospinal fluid
  • Use of high-dose corticosteroids or systemic chemotherapy close to leukapheresis or CAR T cell infusion
  • History of severe heart conditions or recent cardiac events within 6 months
  • Significant autoimmune or inflammatory CNS disease
  • Recent systemic treatment for graft versus host disease
  • Known severe autoimmune diseases likely requiring immune suppression
  • HIV infection
  • Active hepatitis B or C infection
  • Uncontrolled systemic infections including COVID-19 at time of leukapheresis or infusion
  • Other uncontrolled medical, psychological, social, or logistical issues interfering with study compliance
  • Treatment with live, attenuated vaccines within 4 weeks prior to leukapheresis
  • Pregnant or lactating/breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States, 07920

Actively Recruiting

2

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, United States, 07748

Actively Recruiting

3

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

4

Memorial Sloan Kettering Cancer Suffolk-Commack (Limited Protocol Activities)

Commack, New York, United States, 11725

Actively Recruiting

5

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States, 10604

Actively Recruiting

6

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States, 10065

Actively Recruiting

7

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, United States, 11553

Actively Recruiting

Loading map...

Research Team

J

Jae Park, MD

CONTACT

M

Mark Geyer, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here